<DOC>
	<DOCNO>NCT00472823</DOCNO>
	<brief_summary>The purpose study examine effect several dos vitamin D hormone relate bone , calcium absorption , bone density muscle strength .</brief_summary>
	<brief_title>Vitamin D Supplementation Older Women</brief_title>
	<detailed_description>The prevalence osteoporosis high United States , 10 million people age 50 already disease another 34 million risk develop . Development low-cost effective strategy important prevent osteoporosis reduce osteoporotic fracture . A simple inexpensive strategy prevent osteoporosis adequate nutrition calcium vitamin D. Serum 25OHD ( 25-hydroxyvitamin D ) accept objective measure vitamin D nutrition . There grow understand serum 25OHD concentration least 30-32 ng/ml need optimal bone health serum parathyroid hormone ( PTH ) concentration reach minimum . There systematic prospective dose response study aim determine optimum amount vitamin D intake require maintain optimum serum 25OHD level population help determine estimate average requirement ( EAR ) recommend dietary requirement ( RDA ) vitamin D. More work determine RDA vitamin D recommend Panel Calcium Related Nutrients Food Nutrition Board . This study aim fill information gap concentrate high risk group postmenopausal woman . We test theory increase serum 25OHD level great 30 ng/ml reduce serum PTH high risk group vitamin D insufficient postmenopausal woman adequate intake calcium . We also believe dose vitamin D achieve level approximately 4400IU per day , well suggested adequate intake 400-600 ID recommend elderly . In one year double blind , randomize prospective clinical trial , examine dose response effect supplementation different dos vitamin D3 ( 400 , 800 , 1600 , 2400 , 3200 , 4000 , 4800IU/day ) primary outcome serum 25OHD PTH 160 postmenopausal Caucasian 160 African American woman inadequate vitamin D level winter . We expect result study add useful important information RDA vitamin D postmenopausal woman susceptible osteoporosis . The result study also help design future clinical trial study effect vitamin D , example preventing fracture , fall , cancer . The main objective current proposal study effect increase dos vitamin D3 high risk group postmenopausal Caucasian African American woman hypovitaminosis D ( serum 25OHD &lt; 20 ng/ml ) winter presence sufficient calcium intake , order determine Estimated Average Requirement ( EAR ) cover 50 % Recommended Daily allowance ( RDA ) cover 97.5 % population vitamin D. We use serum 25OHD concentration equal &gt; 30 ng/ml normalization serum PTH indicator adequacy . We expect result proposal add important information helpful designing future large clinical trial determine recommend dietary allowance ( RDA ) vitamin D ethnic group design clinical trial effect vitamin D fall fracture . We hypothesize increase serum 25OHD level great 30 ng/ml vitamin D supplement 97 percent study subject reduce serum PTH bone marker premenopausal range . We postulate RDA vitamin D achieve serum 25OHD â‰¥ 30 ng/ml 97.5 % woman winter approximately 4400 IU/d EAR dose vitamin D 800-1000 IU . The specific aim proposal , 1 . To examine dose response effect vitamin D3 , 400 , 800 , 1600 , 2400 , 3200 , 4000 , 4800 IU /d postmenopausal Caucasian African American woman hypovitaminosis D ( serum 25OHD equal &lt; 20 ng/ml ) winter plus adequate calcium intake compare calcium control group , serum 25OHD PTH level , constitute primary outcome measure . 2 . To determine EAR RDA postmenopausal woman establish dose vitamin D3 increase serum 25OHD 30 ng/ml 97.5 % study subject winter reduce serum PTH normal premenopausal range . 3 . To study dose response effect vitamin D3 calcium absorption , 1,25-dihydroxyvitamin D3 ( 1,25 ( OH ) 2D3 ) serum calcium , serum bone marker , bone mineral density ( BMD ) fall ( elderly ) ( secondary outcome measure ) 4 . To establish long term safety dose relate hypercalcemia hypercalciuria Progress : Caucasian enrollment complete July 2008 ; African American enrollment complete May 2009</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<criteria>At least 7 year postmenopause Serum 25OHD level 5 ng/ml 20 ng/ml BMI le equal 40 kg/m2 Willing discontinue multivitamin contain vitamin D study Cancer ( except basal cell carcinoma ) terminal illness Previous hip fracture Hemiplegia ( paralysis one side body ) Uncontrolled type I diabetes fast blood sugar great 140 mg type II Kidney stone twice lifetime Chronic renal failure Evidence chronic liver disease , include alcoholism Physical condition severe osteoarthritis , rheumatoid arthritis , heart failure severe enough prevent reasonable physical activity Previous treatment bisphosphonates ( 3 month ) , PTH PTH derivative , ( e.g . Teriparatide Fluoride ) last 6 month Previous treatment within last 6 month calcitonin estrogen Chronic high dose corticosteroid therapy ( 10 mg per day ) 6 month within last 6 month Anticonvulsant therapy High dose thiazide therapy ( 37.5 mg ) 24 hour urine calcium great 290 mg 2 baseline test Serum calcium exceed upper normal limit 2 baseline test Bone Mineral Density Tscore less 3.0 spine hip</criteria>
	<gender>Female</gender>
	<minimum_age>57 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>cholecalciferol</keyword>
	<keyword>vitamin D deficiency</keyword>
	<keyword>bone density</keyword>
	<keyword>dietary calcium</keyword>
	<keyword>hypercalcemia</keyword>
	<keyword>hypercalciuria</keyword>
</DOC>